Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Contact:
- Weixian T Xu
- Phone Number: 13810695447
- Email: xwxbird05@163.com
-
Contact:
- Xin Liu
- Phone Number: 18801362704
- Email: liuxinlucile2019@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with breast cancer (18-70 years old)
- Patients who are planning to undergo trastuzumab for the first time
Exclusion Criteria:
- Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy
- liver and kidney failure
- severe cerebrovascular disease
- chronic obstructive pulmonary disease
- rheumatic immune system disease
- other tumors
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Women with breast cancer using trastuzumab
|
30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time ending
Time Frame: 6 months
|
180 days after chemotherapy
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Breast Diseases
- Drug-Related Side Effects and Adverse Reactions
- Radiation Injuries
- Breast Neoplasms
- Cardiotoxicity
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Trastuzumab
Other Study ID Numbers
Other Study ID Numbers
- Cardiac safety study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.